Literature DB >> 22539481

Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.

Emily McKeown1, Vivian P Bykerk, Faye De Leon, Ashley Bonner, Carter Thorne, Carol A Hitchon, Gilles Boire, Boulos Haraoui, Diane S Ferland, Edward C Keystone, Janet E Pope.   

Abstract

OBJECTIVE: To characterize steroid use and compliance with glucocorticoid-induced osteoporosis (GIOP) guidelines within a large early inflammatory arthritis cohort.
METHODS: Using the Canadian Early Arthritis Cohort (CATCH) database, patients with inflammatory arthritis on glucocorticoids (oral, IA and i.m.) were identified. Consecutive steroid exposure was defined as using glucocorticoids for two consecutive clinic visits (at least 90 days apart). The primary outcome was the proportion of patients receiving calcium, vitamin D and a bisphosphonate among patients treated with consecutive oral glucocorticoids.
RESULTS: Six hundred and fifty-five patients were in the CATCH database, where 273 patients were identified as glucocorticoid users, of whom 48% were on oral prednisone, 38% received i.m. or IA and 13% both. The median oral daily dose of prednisone was 5 mg (interquartile range 2.5-10). Consecutive users (CUs, n = 78) compared with non-consecutive users (NUs, n = 532) showed that CUs were older (56 vs 50 years, P = 0.001); females were fewer (63% vs 74%, P = 0.04), but a similar proportion were RF positive (51% in CU vs 56% in NU, P = 0.73). For the primary outcome, rates of prophylaxis for users of consecutive oral steroids were as follows: 53% were treated with calcium, 47% with vitamin D and 25% were on a bisphosphonate. For users of oral prednisone at doses ≥7.5 mg/day, rates of prophylaxis were as follows: 64% were treated with calcium, 57% with vitamin D and 21% were on a bisphosphonate.
CONCLUSION: Glucocorticoid therapy is frequently used in early inflammatory arthritis. The use of calcium, vitamin D or a bisphosphonate was low among chronic glucocorticoid users and illustrates the need for more diligence in patients receiving glucocorticoids to prevent GIOP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539481     DOI: 10.1093/rheumatology/kes079

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.

Authors:  Katinka Albrecht; Johanna Callhoff; Matthias Schneider; Angela Zink
Journal:  Rheumatol Int       Date:  2015-02-08       Impact factor: 2.631

Review 2.  Glucocorticoid-induced osteoporosis: 2019 concise clinical review.

Authors:  G Adami; K G Saag
Journal:  Osteoporos Int       Date:  2019-02-25       Impact factor: 4.507

3.  Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.

Authors:  A Balasubramanian; S W Wade; R A Adler; C J F Lin; M Maricic; C D O'Malley; K Saag; J R Curtis
Journal:  Osteoporos Int       Date:  2016-06-08       Impact factor: 4.507

Review 4.  Bisphosphonates for steroid-induced osteoporosis.

Authors:  Claire S Allen; James Hs Yeung; Ben Vandermeer; Joanne Homik
Journal:  Cochrane Database Syst Rev       Date:  2016-10-05

Review 5.  Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis.

Authors:  Estíbaliz Loza; Cristina Lajas; Jose Luis Andreu; Alejandro Balsa; Isidoro González-Álvaro; Oscar Illera; Juan Ángel Jover; Isabel Mateo; Javier Orte; Javier Rivera; José Manuel Rodríguez Heredia; Fredeswinda Romero; Juan Antonio Martínez-López; Ana María Ortiz; Esther Toledano; Virginia Villaverde; Loreto Carmona; Santos Castañeda
Journal:  Rheumatol Int       Date:  2014-12-28       Impact factor: 2.631

Review 6.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

7.  Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.

Authors:  Hasan Abdullah; Greg Koller; Ines Zuna; Nese Yuksel; Theresa Charrois; Rashmi Mandhane; Kathy Cotton; Melanie Danilak; Holly Bell; Carrie Ye
Journal:  Arch Osteoporos       Date:  2021-07-07       Impact factor: 2.617

8.  Tinospora cordifolia: One plant, many roles.

Authors:  Soham Saha; Shyamasree Ghosh
Journal:  Anc Sci Life       Date:  2012-04

9.  Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.

Authors:  Marinella Patanè; Miriam Ciriaco; Serafina Chimirri; Francesco Ursini; Saverio Naty; Rosa Daniela Grembiale; Luca Gallelli; Giovambattista De Sarro; Emilio Russo
Journal:  Adv Pharmacol Sci       Date:  2013-05-12

10.  Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study.

Authors:  Chi Ching Chang; Chi Sheng Chiou; Hsiu Li Lin; Li Hsuan Wang; Yu Sheng Chang; Hsiu-Chen Lin
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.